For instance, liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, achieved resolution of MASH in 39% of patients by improving insulin sensitivity and reducing liver fat. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.